Authors

Latest:

Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer

Lindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.

VK Gadi, MD, PhD

Latest:

Key Takeaways and Closing Thoughts on ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Ryan M. Kahn, MD

Latest:

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Heather Buschman, PhD

Latest:

Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

Study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma

Christina Wu, MD

Latest:

Dr. Wu on the Current Utility of Targeted Therapy in CRC

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.

Melinda Butsch Kovacic, MPH, PhD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Ian Kunkler, FRCP, FRCR, DMRT, MRCP

Latest:

Dr. Kunkler on the 10-Year PRIME 2 Data Examining Post-Surgery Radiation in Breast Cancer

Ian Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer

Anjana Pillai, MD

Latest:

Novel Agents Being Explored in Advanced Biliary Tract Cancers

Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.

Laura M. Kulik, MD, Northwestern

Latest:

Challenges of Sequencing and Biomarkers in HCC

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Yvonne Chao, MD, PhD

Latest:

Dr. Chao on Key Trials Leading to FDA Approvals in Metastatic NSCLC

Yvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.

Kyle A. Blum, MD, MS

Latest:

Dr. Blum on Potential of CA-125 as a Biomarker for Renal Medullary Carcinoma

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

Julien Hadoux, MD, PhD

Latest:

Dr Hadoux on the Efficacy of Selpercatinib in RET-Mutant Medullary Thyroid Cancer

Julien Hadoux, MD, PhD, discusses the efficacy of selpercatinib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 trial.

Jennie W. Taylor, MD, MPH

Latest:

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.

Samuel Rosner, MD

Latest:

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

Ryan M. Kahn, MD, MHS

Latest:

Dr Kahn on the Investigation of Newcastle Disease Virus With IL-12 in Ovarian Cancer

Ryan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.

Marin F. Xavier, MD

Latest:

Dr. Xavier on Recent Updates in DLBCL

Marin F. Xavier, MD, discusses recent updates in diffuse large B-cell lymphoma based on data from the 2021 ASCO Annual Meeting.

Denalee OMalley, PhD

Latest:

Dr. O'Malley on Racial and Economic Barriers to Screening in CRC

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Ann Mohrbacher, MD

Latest:

Future of R/R DLBCL

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Ami P. Vaidya, MD

Latest:

Dr. Vaidya on Advances in the Management of Endometrial Cancer

Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.

Jackie Collins

Latest:

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.